# Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

> **NCT00879814** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Meningitis, Meningococcal

## Interventions

- **BIOLOGICAL:** rLP2086 vaccine or control
- **BIOLOGICAL:** rLP2086 vaccine or control
- **BIOLOGICAL:** rLP2086 vaccine or control
- **BIOLOGICAL:** rLP2086 vaccine or control

## Key facts

- **NCT ID:** NCT00879814
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00879814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00879814, "Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00879814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*